Email This Article

Headlines & Perspectives
Maxim Heading Toward Minimum After FDA Panel Rout
By Dane Hamilton
12/13/00 - 06:52 PM EST
The company's lead drug looks unlikely to be approved in any cancer indication, an analyst says.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,337.05 1,095.94 2,183.73 34.23
Oil *
72.45
UP
51.08
UP
4.01
UP
10.74
UP
0.31
10 Yr
3.42%
SPDR Gold
110.84
+0.50%
+0.37%
+0.49%
+0.91%
Data delayed 20 minutes

Brokerage Partners